We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nike, Inc. (NKE - Free Report) , Salesforce, Inc. (CRM - Free Report) , Zoetis Inc. (ZTS - Free Report) , Archer-Daniels-Midland Co. (ADM - Free Report) and Trane Technologies plc (TT - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Nike, Salesforce and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Inc., Salesforce, Inc. and Zoetis Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Nike have gained +10.2% over the past six month against the Zacks Shoes and Retail Apparel industry's gain of +10.4%. The company gained from brand strength, robust consumer demand and an innovative product pipeline. Its Consumer Direct Acceleration strategy, along with robust performance in its digital and DTC businesses bode well.
Our Model estimates 5.5% revenue growth in fiscal 2023, with 13.2% growth on a currency neutral basis. However, Nike witnessed a decline in gross margin due to higher markdowns to liquidate inventory, increased freight and logistics costs, elevated input costs and currency headwinds.
The Zacks analyst expects soft gross margin and currency headwinds to continue hurting Nike results in the quarters ahead.
Salesforce's shares have outperformed the Zacks Computer - Software industry over the past six months (+19.7% vs. +10.6%). The company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. The rapid adoption of its cloud-based solutions is driving demand for its products. Its sustained focus on introducing more aligned products as per customer needs is driving its top-line.
Continued deal wins in the international market is another growth driver. The acquisition of Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft's Teams product. The Zacks analyst expects CRM's revenues to grow at a CAGR of 11.2% through fiscal 2024-2026.
However, stiff competition and unfavorable currency fluctuations are concerns. Besides, challenging macroeconomic environment might hurt its growth prospects in the near-term.
Shares of Zoetis have outperformed the Zacks Medical - Drugs industry over the past six months (+4.0% vs. -5.4%). The company's momentum continues on its innovative portfolio of pet care parasiticides, including Simparica Trio and dermatology products (Apoquel and Cytopoint). The recently launched chewable version of Apoquel has seen strong growth in sales.
The uptake of Librela and Solensia in Europe, its new monoclonal antibody (mAb) therapies for osteoarthritis pain in dogs and cats, is encouraging. The launch of innovative products bolstered the portfolio and should fuel growth.
However, the company continues to face supply challenges which remain a headwind, along with disease outbreaks in livestock, hurting product demands. Stiff competition from animal health business wings of pharma bigwigs, Merck and Bayer, remains a woe.
Other noteworthy reports we are featuring today include Archer-Daniels-Midland Co. and Trane Technologies plc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies
For Immediate Release
Chicago, IL – March 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nike, Inc. (NKE - Free Report) , Salesforce, Inc. (CRM - Free Report) , Zoetis Inc. (ZTS - Free Report) , Archer-Daniels-Midland Co. (ADM - Free Report) and Trane Technologies plc (TT - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Nike, Salesforce and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Inc., Salesforce, Inc. and Zoetis Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Nike have gained +10.2% over the past six month against the Zacks Shoes and Retail Apparel industry's gain of +10.4%. The company gained from brand strength, robust consumer demand and an innovative product pipeline. Its Consumer Direct Acceleration strategy, along with robust performance in its digital and DTC businesses bode well.
Our Model estimates 5.5% revenue growth in fiscal 2023, with 13.2% growth on a currency neutral basis. However, Nike witnessed a decline in gross margin due to higher markdowns to liquidate inventory, increased freight and logistics costs, elevated input costs and currency headwinds.
The Zacks analyst expects soft gross margin and currency headwinds to continue hurting Nike results in the quarters ahead.
(You can read the full research report on NIKE here >>>)
Salesforce's shares have outperformed the Zacks Computer - Software industry over the past six months (+19.7% vs. +10.6%). The company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. The rapid adoption of its cloud-based solutions is driving demand for its products. Its sustained focus on introducing more aligned products as per customer needs is driving its top-line.
Continued deal wins in the international market is another growth driver. The acquisition of Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft's Teams product. The Zacks analyst expects CRM's revenues to grow at a CAGR of 11.2% through fiscal 2024-2026.
However, stiff competition and unfavorable currency fluctuations are concerns. Besides, challenging macroeconomic environment might hurt its growth prospects in the near-term.
(You can read the full research report on Salesforce here >>>)
Shares of Zoetis have outperformed the Zacks Medical - Drugs industry over the past six months (+4.0% vs. -5.4%). The company's momentum continues on its innovative portfolio of pet care parasiticides, including Simparica Trio and dermatology products (Apoquel and Cytopoint). The recently launched chewable version of Apoquel has seen strong growth in sales.
The uptake of Librela and Solensia in Europe, its new monoclonal antibody (mAb) therapies for osteoarthritis pain in dogs and cats, is encouraging. The launch of innovative products bolstered the portfolio and should fuel growth.
However, the company continues to face supply challenges which remain a headwind, along with disease outbreaks in livestock, hurting product demands. Stiff competition from animal health business wings of pharma bigwigs, Merck and Bayer, remains a woe.
(You can read the full research report on Zoetis here >>>)
Other noteworthy reports we are featuring today include Archer-Daniels-Midland Co. and Trane Technologies plc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.